| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116fa4406381fc82bb76e8657e68788a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D261-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41 |
| filingDate |
2022-05-21^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b942f6e59180e1ebae34659874236a07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecff8ad8d0f7645196b46fb41dc444d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9cd42defb0c3553879c71583a28b7cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86d825df9b8f3b0783d71b1183c7681c |
| publicationDate |
2022-11-24^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022243983-A1 |
| titleOfInvention |
Fused isoxazolyl compounds as kat6a inhibitors |
| abstract |
The present invention provides fused isoxazolyl compound of formula (I), which are therapeutically useful as KAT6A inhibitors particularly in the treatment and/or prevention of diseases or disorders dependent upon KAT6A in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the compound represented by formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof. |
| priorityDate |
2021-05-21^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |